Company Overview - Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for individuals with rare kidney and metabolic diseases in the United States [2]. Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere, specifically whether the company and certain executives made materially false and/or misleading statements or omitted material information regarding Travere's business and operations [1][2]. Law Firm Background - Robbins Geller is recognized as one of the leading law firms in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in securities-related class action cases in 2024, which is more than the next five law firms combined [3].

Company Overview - NuScale Power Corporation is a provider of small modular reactor nuclear technology [2] Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving NuScale Power Corporation [1] - The investigation focuses on whether NuScale and certain top executives made materially false and/or misleading statements or omitted material information regarding the company's business and operations [2]

Core Viewpoint - A class action lawsuit has been filed against Ramaco Resources, Inc. due to allegations of misleading statements regarding the company's Brook Mine operations, which reportedly did not commence significant mining activity as claimed [1][4]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York, under the case caption Henning v. Ramaco Resources, Inc., and covers the period from July 31, 2025, to October 23, 2025 [1]. - The lawsuit claims violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, asserting that the defendants made materially false and misleading statements about the company's business and operations [1][4]. Group 2: Allegations Against Ramaco - Wolfpack Research published a report on October 23, 2025, alleging that Ramaco's Brook Mine was a "hoax" and that no active mining work had occurred since its groundbreaking in July [3]. - The report indicated that drone footage taken three months after the mine's opening showed no active work, contradicting the company's claims of progress [3]. - Following the report, Ramaco's stock price dropped by $3.81, or 9.6%, closing at $36.01 per share on October 23, 2025, with unusually high trading volume [3]. Group 3: Misleading Statements - The complaint alleges that the defendants failed to disclose critical information, including the lack of significant mining activity at the Brook Mine and the overstated development progress [4]. - It is claimed that the positive statements made by the defendants regarding the company's operations were materially misleading and lacked a reasonable basis [4].

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. for allegedly misleading investors regarding tenant demand and funding commitments for its Project Matador campus, leading to significant financial losses for shareholders [4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased securities from September 28, 2025, to December 11, 2025, alleging that Fermi overstated tenant demand and the reliance on a single tenant's funding for Project Matador [4]. - The lawsuit claims there was a significant risk that the primary tenant would terminate its funding commitment, which ultimately occurred [4]. Group 2: Financial Impact - Fermi began trading on NASDAQ at $21.00 per share on October 1, 2025, but after the announcement of the termination of a $150 million funding agreement on December 12, 2025, the share price dropped by $5.16, or approximately 33.8%, closing at $10.09 [5].

Core Viewpoint - The lawsuit against BellRing Brands, Inc. alleges that the company and its executives misled investors regarding the true drivers of its sales growth, which was primarily due to retailers hoarding inventory rather than genuine consumer demand [3][5]. Group 1: Allegations and Misleading Statements - The lawsuit claims that BellRing's reported sales growth in 2025 was not reflective of actual consumer demand but was instead driven by retailers stockpiling inventory to avoid previous supply chain shortages [3][7]. - It is alleged that once retailers felt secure about product availability, they began to destock their excess inventory, leading to a significant drop in BellRing's share price [3][7]. - The CFO of BellRing admitted that some retailers were hoarding inventory during a conference call, which contradicted earlier assurances about stable consumption levels [7]. Group 2: Financial Impact and Market Reaction - Following the revelation of disappointing Q2 2025 results, BellRing's share price fell by $14.88, representing a 19% decline [7]. - On August 4, 2025, after reporting a narrowed sales outlook, BellRing's share price plummeted by $17.46, or 33%, as analysts expressed skepticism about the company's claims regarding competition and consumption [7]. Group 3: Legal Proceedings and Next Steps - The lead plaintiff deadline for the ongoing lawsuit is set for March 23, 2026, and investors who suffered losses during the specified period are encouraged to participate [1][6]. - Hagens Berman, the law firm handling the case, is actively seeking investors who purchased BellRing shares between November 19, 2024, and August 4, 2025 [6].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Bath & Body Works, Inc. for alleged material misstatements and omissions during the class period from June 4, 2024, to November 19, 2025 [2][8]. Group 1: Allegations and Company Performance - The lawsuit claims that Bath & Body Works made materially false and misleading statements regarding its business strategy and financial performance [3]. - It is alleged that the company's strategy of pursuing "adjacencies, collaborations and promotions" did not effectively grow the customer base or deliver the expected growth in net sales [3]. - The complaint indicates that as the company's strategy faltered, it relied on brand collaborations to mask weak financial results, leading to a failure to meet previously issued financial guidance [3]. Group 2: Legal Process and Investor Information - Investors affected by the alleged fraud can seek to be appointed as lead plaintiffs by March 16, 2026, through Kessler Topaz Meltzer & Check, LLP [5]. - The lead plaintiff will represent all class members in directing the litigation and selecting counsel [5]. - Kessler Topaz Meltzer & Check, LLP encourages affected investors to contact them for more information regarding potential recovery of investment losses [6].

Core Viewpoint - A class action lawsuit has been filed against Bath & Body Works, Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1]. Company Overview - Bath & Body Works is a specialty retailer focused on home fragrance and body care products, exploring product categories beyond its core business, including men's products, lip care, hair care, and laundry items [4]. Financial Performance - On August 28, 2025, Bath & Body Works reported disappointing Q2 2025 results, cutting its full-year earnings guidance by $0.03 to a range of $3.28 to $3.53 per diluted share, leading to a stock price drop of $2.18, or 6.9%, from $31.54 to $29.36 [6]. - Following the Q3 2025 results on November 20, 2025, which included a further reduction in full-year guidance and acknowledgment that the strategy of pursuing adjacencies had not grown the customer base, the stock fell by $5.22, or 24.8%, from $21.04 to $15.82 [7]. Legal Context - Investors have until March 16, 2026, to request to lead the case in the ongoing lawsuit, which is filed under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. - Investors have until March 9, 2026, to request to lead the case, with claims asserted under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections" while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health disclosed a $43 million revenue decrease for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, below analysts' expectations, and projected poor net sales growth of -2% to 2% for 2026. This led to a stock price drop of $35.22 per share, over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - Carvana Co. is under investigation for potential violations of federal securities laws due to significant stock price drops linked to claims of accounting improprieties [1][2]. Company Overview - Carvana operates as an online e-commerce platform and used-car retailer, facilitating the buying, selling, and financing of vehicles entirely online. A major portion of its revenue is derived from online vehicle sales and auto loans, which are often securitized or sold to external parties [3]. Investigation Details - The investigation by Bleichmar Fonti & Auld LLP focuses on whether Carvana overstated its earnings and improperly accounted for related party transactions [3]. - Gotham City Research LLC released a report indicating that Carvana's financial results are closely connected to a network of related party entities controlled by Ernest Garcia II, which includes DriveTime, Bridgecrest, and GoFi. The report claims that these relationships have led to an overstatement of Carvana's earnings by over $1 billion, raising substantial risks for investors [4]. Stock Performance - Following the release of the Gotham City report on January 28, 2026, Carvana's stock price fell over 20%, dropping from $474.06 per share at market open to a low of $374.55 per share [5].